Ceritinib
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Ceritinib: From ALK-Positive Non-Small Cell Lung Cancer to Gingival Fibromatosis
One-Sentence Summary
Ceritinib is a second-generation ALK/ROS1 tyrosine kinase inhibitor originally developed for ALK-positive advanced non-small cell lung cancer (NSCLC). The TxGNN model’s top-ranked prediction for this drug is Gingival Fibromatosis (a benign gum fibrous overgrowth condition), but this prediction is currently supported by 0 clinical trials and 0 publications, and the underlying evidence assessment explicitly flags it as likely model noise rather than a genuine biological signal.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | ALK-positive (ALK-rearranged) advanced non-small cell lung cancer (NSCLC) (sourced from supporting literature in this evidence pack, e.g. PMID 24980964, PMID 28126333) |
| Predicted New Indication | Gingival Fibromatosis (Fibromatosis, gingival) |
| TxGNN Prediction Score | 99.86% |
| Evidence Level | L5 |
| Australia Market Status | Not Marketed |
| Number of ARTG Entries | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action (MOA) data is not directly available for this evidence pack (flagged as a High-severity data gap). Based on information drawn from the supporting literature, Ceritinib is a second-generation ALK/ROS1 tyrosine kinase inhibitor (TKI). Its efficacy in ALK-rearranged NSCLC has been demonstrated in multiple Phase 3 trials (e.g. the ASCEND-4 study), and mechanistically it acts by inhibiting ALK and ROS1 signal transduction in ALK-driven tumours.
Gingival fibromatosis, however, is a benign fibroproliferative condition affecting the gingival soft tissue. There is no known biological pathway connecting ALK/ROS1 kinase inhibition to the pathogenesis of gingival fibrous overgrowth, and no clinical trial or literature evidence in this evidence pack links the two. The repurposing rationale attached to this candidate explicitly characterises it as model noise rather than a genuine mechanistic hypothesis.
Given the absence of any mechanistic rationale, clinical trial data, or literature support, this specific prediction should not be interpreted as a credible repurposing signal. It is presented here transparently because it is the TxGNN model’s highest-scoring output for this drug, but the score alone (based on embedding similarity) is insufficient to establish biological plausibility. Other lower-ranked predictions in the wider candidate set (e.g. anatomically NSCLC-adjacent entities such as lung hilum carcinoma or pulmonary sulcus neoplasm) carry a more defensible class-level rationale, though none currently reach a level of evidence beyond exploratory “Research Question” status.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Australia Market Information
Ceritinib currently has no ARTG entries and is not marketed in Australia (0 licences on record in this evidence pack).
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy (ALK/ROS1 tyrosine kinase inhibitor) |
| Myelosuppression Risk | Please refer to the Product Information (PI) warnings and precautions |
| Emetogenicity Classification | Please refer to the Product Information (PI) warnings and precautions |
| Monitoring Items | Liver function tests, ECG/QTc interval, and gastrointestinal symptoms — consistent with known ALK-TKI class safety signals reported in the supporting literature (e.g. QT prolongation and cardiovascular monitoring in TKIs) |
| Handling Protection | Please refer to the Product Information (PI) warnings and precautions |
Safety Considerations
Please refer to the TGA-approved Product Information (PI) for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale:
- The top-ranked prediction (gingival fibromatosis) has a high TxGNN score (99.86%) but zero supporting clinical trials, zero literature, and no plausible mechanistic link to Ceritinib’s known ALK/ROS1 target — the evidence assessment itself identifies this as likely model noise.
To proceed, the following is needed:
- Detailed mechanism of action (MOA) data via DrugBank API (currently a data gap)
- TFDA/TGA-approved Product Information for warnings, contraindications, and drug interactions (currently a Blocking data gap preventing safety pre-screening)
- If pursuing alternative candidates from the same prediction set (e.g. lung hilum carcinoma, pulmonary sulcus neoplasm), independent verification of TxGNN disease-node mapping accuracy and dedicated clinical trial/literature searches specific to those indications
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.